We advocate for compounding pharmacies and facilities on a range of state and federal issues affecting patient access to compounded medications. We represent pharmacists and technicians in both traditional 503A compounding pharmacies and 503B outsourcing facilities, as well as prescribers, patients, educators, and suppliers. We’re 5,000 members strong and growing.
An update on state legislation and changes impacting compounding pharmacies – May 1, 2026.
APC has launched a first-of-its-kind compounding dispensing data reporting initiative, and we need your pharmacy to be part of it. Learn more!
The FDA today proposed to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list. Here's what you should know.
APC is reviewing the FDA’s proposed rule addressing the 503B Bulks List, including the proposal not to include liraglutide, semaglutide, and ...
State updates on the latest bills and policy impacting compunding pharmacists.
.png?width=410&height=320&name=image-container%20(1).png)
.png?width=410&height=320&name=image-container%20(2).png)
.png?width=411&height=320&name=image-container%20(3).png)
.png?width=410&height=320&name=image-container%20(4).png)
.png)
.png?width=17&height=16&name=folder%20(1).png){kind=small}
%20Pharma-GS.png)
